ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 65 citations in OpenAlex.
- Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2025Trial
- PD-L1 PET/CT imaging withEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Immune landscape of melanoma: Tumor microenvironment, resistance mechanisms, and predictive biomarkers.World journal of clinical oncology · 2026Review
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.Melanoma research · 2025Article
- Synthesis and preclinical evaluation of small molecule-based radiotracers for PET imaging of PD-L1 expression and dynamics.European journal of nuclear medicine and molecular imaging · 2025Article
- Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Novel Clinical PET Tracers in the Pipeline for Melanoma.Current oncology reports · 2025Review
- Recent Updates of PET in Lymphoma: FDG and Beyond.Biomedicines · 2024Review
- Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool.Science advances · 2024Article
- Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.Journal for immunotherapy of cancer · 2024Article
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured byJournal for immunotherapy of cancer · 2024Article
- Article
- Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.European journal of nuclear medicine and molecular imaging · 2024Article
- Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1.European journal of nuclear medicine and molecular imaging · 2024Article
- PET imaging of PD-L1 with a small molecule radiotracer.European journal of nuclear medicine and molecular imaging · 2024Article
- The discovery and evaluation of [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) frequently induces tumor response in metastatic melanoma patients. However, tumor response often takes months and may be heterogeneous. Consequently, additional local treatment for nonresponsive metastases may be needed, especially in the case of brain metastases. Noninvasive imaging may allow the characterization of (brain) metastases to predict response. This pilot study uses
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.